Shattuck Labs, Inc. (STTK) AI Stock Analysis

Shattuck Labs, Inc. is an Austin, Texas-based clinical-stage biotechnology company focused on novel treatments for cancer and autoimmune diseases. The company's lead product candidate, SL-172154, is in Phase 1 clinical trials targeting ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs is also advancing SL-279252 through Phase 1 clinical trials for patients suffering from advanced solid tumors and lymphoma. Established in 2016, the company utilizes proprietary technology platforms to address critical unmet patient needs across oncology and autoimmune disorders with an internal team of 40 employees.

Annual revenue has fluctuated heavily, moving from $30.0M in FY2021 down to $652,000 in FY2022, before reaching $1.7M in FY2023 and $5.7M in FY2024. In FY2025, revenue fell 82.5% to $1.0M, resulting in a 5-year revenue compound annual growth rate of -36.8%. Net losses were -$45.0M in FY2021, -$100.6M in FY2022, -$87.3M in FY2023, -$75.4M in FY2024, and -$48.8M in FY2025. Operating margin in FY2025 was -5150.8%, alongside a net margin of -4880.9%. For the latest quarter ended June 30, 2026, quarterly revenue dropped 66.6% year-over-year, while trailing twelve months revenue totaled $1.0M with diluted EPS of -$0.47.

As of June 30, 2026, Shattuck Labs held $63.3M in cash and short-term investments against total debt of $2.7M, yielding net cash of $60.6M. The company maintains a current ratio of 27.59 and a debt-to-equity ratio of 0.01 on shareholders' equity of $211.1M. Operating cash flow in FY2025 was -$39.9M, and free cash flow stood at -$40.0M after capital expenditures of $71,000. Over five years, the company's share count expanded by 190.1%.

Shattuck Labs trades at a price-to-sales multiple of 544.0x and an enterprise-value-to-revenue multiple of 433.7x, compared to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 3.0x. Over the past year, STTK shares advanced 201.1%, significantly outpacing the 16.8% return of the S&P 500 (SPY). Over a 5-year horizon, the stock dropped 72.0%, while the S&P 500 gained 83.0%. The stock closed at $5.42 on October 16, 2026, which is 9.2% below its 200-day moving average.

Wall Street coverage consists of 9 Strong Buy ratings, 3 Buy ratings, and 0 Hold or Sell recommendations. The consensus mean price target is $15.40, representing an implied upside of 184.1% above the October 16, 2026 closing price of $5.42. For the fiscal year ending December 31, 2026, analysts estimate EPS of -$0.48 and revenue of $111,110. For the following fiscal year, 11 analysts project EPS of -$0.52 and revenue of $111,110. Shattuck Labs beat EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for November 5, 2026.

This page is an AI-written research summary of Shattuck Labs, Inc. (STTK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: STTK income statement, STTK balance sheet, STTK key metrics, STTK analyst forecast, STTK chart. See the STTK stock overview for the latest quote and news.